Adults with Migraine have new reason to be hopeful. 2019 saw FDA approval of new acute Migraine medications, and 2020 will be the year thousands of adults with Migraine with or without aura will get to try new meds like Ubrelvy (ubreogepant).
Ubrelvy is an oral CGRP inhibitor – the first of its kind to be approved. Alongside Reyvow (lasmiditan) and other meds in the gepant class, it offers a new option for the many people with Migraine who cannot tolerate or who are not helped by triptans.
Injectible, preventative drugs targeting CGRP were approved last year, including Aimovig, Ajovy, and Emgality. The newly approved drug is different because it can be taken orally and is designed to stop a Migraine attack in progress.
It brings a new option – and a lot of hope – to the headache and Migraine community.
If you’re an adult with Migraine in the United States who’s been searching for a medication that actually stops your attacks, you now have a new option. This is really good news for people who can’t take triptans due to contraindications, and for those whose Migraine symptoms aren’t relieved by triptans.
Ubrelvy Fast Facts
- It is the first and only oral CGRP receptor antagonist (gepant) approved for the acute treatment of Migraine
- It is approved at two dose strengths (50-mg and 100-mg) for Migraine with and without aura in adults only
- Ubrelvy is not approved to prevent Migraine
- The most common side effects reported in clinical trials were nausea, tiredness, and dry mouth
- Clinical trials showed one dose of Ubrelvy eliminated patients’ Migraine pain and their most bothersome symptoms compared to placebo at two hours (1
“Approval of ubrogepant, an orally available CGRP blocker, that is effective in the treatment of Migraine attacks, means I can look my patients in the eye and say: we have something new when other things have failed,” headache specialist Dr. Peter Goadsby told Migraine Again.
“I can look a patient with intolerable side effects or safety issues with current medications, in the eye and say: I have something better. Best of all, I can say, although it sometimes feels no one cares and you are abandoned; you are not abandoned, we do care and thousands have worked on new treatments because your problem is important to me and many others.” Dr. Goadsby is a world-renowned clinician and a Professor of Neurology at the University of California, San Francisco.